Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ImmunityBio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.04
0.05
0.05
2.2
0.61
0.93
0.24
0.62
14.7
113
Cost of revenue
0
0
0
0.75
Gross profit
0.24
0.62
14.7
113
Research and development
29.2
42
55.7
112
140
196
248
232
190
Selling, general and administrative
95.4
57.1
42.7
46.5
71.3
135
103
130
169
Operating expenses
125
99.2
98.4
158
221
331
352
363
359
Operating income
-125
-99.1
-98.4
-156
-221
-330
-351
-362
-344
-256
Interest expense
0.07
0.62
5.92
9.07
14.8
63.5
129
115
60.9
Interest income
5.17
4.23
2.32
1.64
1.23
Other non-operating income
3.12
2.2
1.66
-4.01
-5.15
-19.6
-66
-222
-69.5
-95.6
Pre-tax income
-121
-96.9
-96.7
-160
-226
-350
-417
-584
-414
-352
Income tax
-0.57
-0.49
-0.5
-0.11
-1.85
0.01
0.03
-0.04
0
-0.14
Net income to minority interests
-2.38
-2.34
-3.06
-0.75
-0.66
-0.08
-0.07
Net income
-121
-96.4
-96.2
-158
-222
-347
-417
-583
-414
-351
EBITDA
-121
-93.6
-88.8
-142
-208
-316
-333
-344
-327
-241
EPS, basic
-0.90
-0.74
-0.75
-0.43
-0.59
-0.89
-1.04
-1.15
-0.59
-0.38
EPS, diluted
-0.90
-0.74
-0.75
-0.43
-0.59
-0.89
-1.04
-1.15
-0.62
-0.38
Shares, basic (weighted)
133
131
129
366
377
389
400
509
697
920
Shares, diluted (weighted)
133
131
129
366
377
389
400
509
700
920
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
8.08
23.9
16.8
75.8
34.9
181
105
265
143
88.3
Short-term investments
191
104
57.3
36.1
61.1
136
2.54
1.01
6.38
154
Receivables
0
2.36
42.6
Inventory
0
8.27
0.91
Other current assets
0.28
0.28
0.04
0.02
0.11
2.96
1.98
1.54
1.3
2.14
Total current assets
205
132
88.8
55.8
112
334
141
294
185
315
Property, plant and equipment
18.9
76.7
76.9
60.5
72.5
82.9
144
146
137
114
Lease right-of-use assets
0
11.7
18.1
36.3
45.8
36.5
33.4
33
Goodwill
0.91
0.91
Intangible assets
5.09
2.83
0.57
0
1.46
1.42
20
17.1
14.5
13
Long-term investments
87.6
29.6
5.7
1.5
0.95
0.82
0.84
0.89
0
Other non-current assets
0.79
0.33
1.53
4.39
2.6
6.78
4.86
2.88
4.83
Total assets
317
250
182
143
221
469
362
504
383
502
Accounts payable
4.05
5.87
2.79
1.75
11.5
11.4
21
Accrued liabilities
5.86
11.3
21.1
5.34
36.8
51.4
41.8
42.7
40.6
46.8
Short-term debt
1.25
1.75
Total current liabilities
12.6
20.9
27.3
11.6
68.1
369
501
58.3
54.9
61.8
Lease liabilities
0
10.9
16.2
37.1
48
39.9
34.8
33.4
Other non-current liabilities
0.24
0.26
0
1.04
0.41
0.46
1.11
0.32
0.42
Total liabilities
24.1
31.6
35.9
22.4
340
713
812
1,090
871
1,001
Paid-in capital
681
718
741
783
1,495
1,720
1,931
2,375
2,885
3,197
Retained earnings
-387
-499
-595
-662
-1,615
-1,962
-2,378
-2,962
-3,375
-3,727
Other comprehensive income
-0.28
-0.38
-0.27
-0.11
0.12
0
0.18
0.01
1.2
29
Shareholders' equity
293
219
146
121
-120
-242
-447
-587
-489
-500
Minority interests
1.32
-1.74
-2.49
1.05
0.97
0.9
Total equity
293
219
81.9
16.3
-118
-244
-450
-586
-488
-500
Total liabilities and equity
317
250
182
143
221
469
362
504
383
502
Shares outstanding
133
129
129
98.5
382
398
422
671
853
1,012
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-121
-96.4
-96.2
-160
-224
-350
-417
-584
-414
-351
Depreciation and amortization
3.61
5.57
9.56
14
12.7
14.2
18.3
18.5
17.6
15.5
Stock-based compensation
73.9
37
23.4
3.42
2.19
57.2
40.2
49.2
34.4
36.8
Deferred income tax
-0.58
-0.5
-0.5
-0.01
-2.94
-0.01
-0
-0.01
0
-0.14
Change in receivables
0
0
-2.36
-40.2
Change in inventory
0
0
-8.27
-6.33
Change in payables
0.89
0.15
-1.1
Cash from operations
-38.6
-48.8
-63.4
-152
-172
-274
-338
-367
-391
-305
Capital expenditures
-6.56
-34.8
-13.1
-4.29
-1.67
-33.6
-78.2
-30.6
-6.89
-3.85
Acquisitions
0
0
0
0
-1
0
Purchases of investments
0
-8.5
0
-86.6
-91.6
-142
-34.3
-10.4
-140
-241
Sales and maturities of investments
166
254
165
110
65.4
56.2
128
10.1
116
64.9
Cash from investing
-114
99.6
57.1
18.6
-19.8
-84.9
27.3
-30.5
-12.2
-150
Debt repaid
0
0
-1.13
Stock issued
0
1.15
0
30
86.3
165
60.4
0.29
Share buybacks
-15.8
-15.2
-0.23
-2.5
0
0
Cash from financing
-15.6
-35
-0.77
114
151
505
234
558
282
400
Net change in cash
-168
15.8
-7.05
-19.3
-40.9
146
-76.3
161
-122
-54.5
Free cash flow
-45.2
-83.6
-76.5
-156
-173
-308
-416
-397
-398
-309
Interest paid
0.07
0.67
0.48
0.02
0.04
2.11
35.4
77.2
92.3
71.3
Income taxes paid
0
0
0
0
0.01
0.01
0
0.01
0.02
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.44 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
99.3%
Gross profit / revenue.
Operating margin
-151.9%
Operating income / revenue.
EBITDA margin
-142.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-598.7%
Pre-tax income / revenue.
Net margin
-598.6%
Net income / revenue.
FCF margin
-173.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-169.6%
Cash from operations / revenue.
Return on assets (ROA)
-157.9%
Net income / average total assets.
Stock-based pay / revenue
20.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
4.2%
Capital expenditures / revenue.
D&A / revenue
9.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
668.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
678.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
184.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
663.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
676.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
31.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
11.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
17.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
31.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
32.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
19.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.72x
Current assets / current liabilities.
Quick ratio
5.35x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.66x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.16
Revenue / diluted weighted shares.
FCF per share
-$0.27
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.27
Cash from operations / diluted weighted shares.
Book value per share
-$0.99
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
54.0x
Market cap / revenue.
EV/Sales
51.8x
Enterprise value / revenue.
FCF yield
-3.2%
Free cash flow / market cap.
Earnings yield
-11.1%
Net income / market cap (the inverse of P/E).
What was ImmunityBio, Inc.'s revenue in fiscal 2025?
ImmunityBio, Inc. reported revenue of $113.3M for fiscal 2025, 668.3% higher than the year before.
Was ImmunityBio, Inc. profitable in fiscal 2025?
No. It reported a net loss of $351.4M.
How much free cash flow did ImmunityBio, Inc. generate in fiscal 2025?
Cash from operations of $304.9M minus capital expenditures of $3.8M left free cash flow of -$308.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.